Related Experiment Video
Updated: Jan 19, 2026
FDA Approved Drugs: Changes to Approved Drugs
Published on: October 3, 2025
Development Times and Approval Success Rates for Drugs to Treat Infectious Diseases
Joseph A DiMasi1, Maria I Florez1, Stella Stergiopoulos1
1Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, USA.
Abstract:
We gathered data from three pipeline databases and other public sources on development stage and clinical trial metrics for 1,914 investigational drugs, biologics, and vaccines and 2,769 clinical trials intended to treat a wide variety of infectious diseases. We included new molecular entities (NMEs), new formulations, and new combinations. Clinical trial times decreased from 2000-2008 to 2009-2017, varied by disease class, and were longer for trials with more subjects or more sites. Clinical approval success rates were higher for this set of diseases than those in the published literature for drugs across all therapeutic categories. NMEs to treat HIV had a success rate (16.0%) that was similar to those for drugs in general, whereas NME success rates for influenza and pneumonia were much higher (48.1% and 50.5%, respectively).
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
14:34Biocontained Carcass Composting for Control of Infectious Disease Outbreak in Livestock
10:03Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
11:51Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
03:22Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases
07:50Assay Development for High-Throughput Drug Screening Against Mycobacteria

